MVCD5
MCID: MCR115
MIFTS: 65

Microvascular Complications of Diabetes 5 (MVCD5)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 5

MalaCards integrated aliases for Microvascular Complications of Diabetes 5:

Name: Microvascular Complications of Diabetes 5 57 73 29 13 6 37 39
Diabetic Retinopathy 12 36 54 44 15 17 71 32
Retinopathy, Diabetic 57 74
Diabetic Nephropathy 73 71
Mvcd5 57 73
Microvascular Complications of Diabetes, Susceptibility to, 5 57
Retinopathy, Diabetic, Susceptibility to 57
Retinal Abnormality - Diabetes-Related 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8947
OMIM® 57 612633
OMIM Phenotypic Series 57 PS603933
KEGG 36 H01457
ICD9CM 34 362.0
NCIt 50 C34538
SNOMED-CT 67 154678005
ICD10 32 H36.0
MedGen 41 C2674665
UMLS 71 C0011881 C0011884

Summaries for Microvascular Complications of Diabetes 5

KEGG : 36 Diabetic retinopathy (DR), one of the most common vascular complication of diabetes, is the leading cause of visual deficits and blindness around the world. The development of DR is divided into two stages: in the early stages, also called as nonproliferative stage, it is asymptomatic because the signs are not visible to the eye. however, some defects including microaneurysms, intraretinal hemorrhaging, narrowing or blocked retinal blood vessels can be seen by detection; in the second stage, known as proliferative diabetic retinopathy, where neovascularization appears at the back of the eye and extend into the vitreous of the eye, and these new blood vessels are fragile. If they leak blood, the bleeding causes shrinkage of the retina, leading to retinal detachment, and ultimately to blindness. It has been reported that vascular endothelial growth factor A, angiotensin-converting enzyme, paraoxonase, erythropoietin are associated with DR development and progression.

MalaCards based summary : Microvascular Complications of Diabetes 5, also known as diabetic retinopathy, is related to microvascular complications of diabetes 1 and diabetic angiopathy. An important gene associated with Microvascular Complications of Diabetes 5 is PON1 (Paraoxonase 1), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and HIF-1 signaling pathway. The drugs Zaleplon and Acarbose have been mentioned in the context of this disorder. Affiliated tissues include Eye, and related phenotypes are cardiovascular system and homeostasis/metabolism

UniProtKB/Swiss-Prot : 73 Microvascular complications of diabetes 5: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

Wikipedia : 74 Diabetic retinopathy, also known as diabetic eye disease (DED), is a medical condition in which damage... more...

More information from OMIM: 612633 PS603933

Related Diseases for Microvascular Complications of Diabetes 5

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 2 Microvascular Complications of Diabetes 3
Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 5
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 5 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 797)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 32.7 VEGFA SERPINF1 PGF INS IGF1 ICAM1
2 diabetic angiopathy 32.5 NOS3 INS AGER
3 type 1 diabetes mellitus 32.4 VEGFA PON1 INS IGF1 ICAM1 ALB
4 maturity-onset diabetes of the young, type 1 32.4 INS ALB ACE
5 retinal detachment 32.3 VEGFA SERPINF1 IGF1 FGF2
6 microvascular complications of diabetes 3 32.3 INS ALB AKR1B1 AGER ACE
7 macular holes 32.0 VEGFA SERPINF1 ANGPT2
8 retinal microaneurysm 32.0 VEGFA INS AKR1B1
9 lipid metabolism disorder 31.8 SERPINE1 PON1 INS ACE
10 type 2 diabetes mellitus 31.8 VEGFA SERPINE1 PRKCB PON1 NOS3 KDR
11 cataract 31.7 VEGFA SERPINF1 INS IGF1 ICAM1 FGF2
12 leukostasis 31.7 VEGFA SERPINF1 KDR ICAM1 AGER
13 eye disease 31.7 VEGFA SERPINF1 PRKCB PGF KDR INS
14 proteinuria, chronic benign 31.7 VEGFA FLT1 ALB ACE
15 rubeosis iridis 31.7 VEGFA INS
16 kidney hypertrophy 31.5 INS ALB ACE
17 retinal vein occlusion 31.5 VEGFA SERPINF1 SERPINE1 KDR ANGPT2 ACE
18 retinal vascular disease 31.4 VEGFA TEK SERPINF1 PGF NOS3 KDR
19 autonomic neuropathy 31.4 INS ALB AKR1B1
20 endophthalmitis 31.4 VEGFA PGF ICAM1 FLT1 ALB
21 coronary heart disease 1 31.3 SERPINE1 PON1 INS ACE
22 peripheral nervous system disease 31.3 VEGFA INS IGF1 FGF2 ALB AKR1B1
23 homocysteinemia 31.3 SERPINE1 PON1 NOS3 ALB
24 vascular disease 31.2 VEGFA SERPINE1 PON1 NOS3 INS IGF1
25 diabetic neuropathy 31.2 VEGFA PRKCB INS ICAM1 FGF2 AKR1B1
26 end stage renal disease 31.2 VEGFA PON1 NOS3 INS ICAM1 ALB
27 hypertensive nephropathy 31.2 VEGFA ALB ACE
28 peripheral vascular disease 31.2 VEGFA SERPINE1 ALB ACE
29 polyneuropathy 31.1 VEGFA INS ALB AKR1B1 ACE
30 diabetic cataract 31.1 VEGFA SERPINF1 AKR1B1
31 open-angle glaucoma 31.1 VEGFA SERPINE1 NOS3 ALB ACE
32 keratopathy 31.1 IGF1 ICAM1 AKR1B1
33 kidney disease 31.1 VEGFA SERPINE1 PRKCB PON1 NOS3 INS
34 hypothyroidism 31.0 VEGFA PON1 INS IGF1 ALB ACE
35 diabetic polyneuropathy 31.0 VEGFA NOS3 AKR1B1 AGER
36 atherosclerosis susceptibility 31.0 VEGFA SERPINE1 PON1 NOS3 INS ICAM1
37 ischemia 31.0 VEGFA TEK PON1 NOS3 KDR ICAM1
38 cerebrovascular disease 30.9 SERPINE1 PON1 INS ICAM1 AGER ACE
39 chronic kidney disease 30.9 VEGFA SERPINE1 PON1 NOS3 INS IGF1
40 arteries, anomalies of 30.9 VEGFA SERPINE1 NOS3 INS ICAM1 ALB
41 carotid stenosis 30.9 VEGFA NOS3 ICAM1 ACE
42 deficiency anemia 30.9 PON1 INS IGF1 ALB ACE
43 sleep apnea 30.9 VEGFA SERPINE1 NOS3 INS IGF1 ICAM1
44 renal hypertension 30.9 NOS3 ALB ACE
45 congestive heart failure 30.9 VEGFA NOS3 INS ALB ACE
46 peripheral artery disease 30.9 VEGFA NOS3 ICAM1 FGF2 ANGPT2 ACE
47 glucose intolerance 30.8 NOS3 INS IGF1 ALB ACE
48 kuhnt-junius degeneration 30.8 VEGFA TEK SERPINF1 PGF KDR FLT1
49 exanthem 30.8 VEGFA ALB ACE
50 stroke, ischemic 30.8 SERPINE1 PON1 NOS3 MIAT ALB ACE

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 5:



Diseases related to Microvascular Complications of Diabetes 5

Symptoms & Phenotypes for Microvascular Complications of Diabetes 5

Clinical features from OMIM®:

612633 (Updated 05-Mar-2021)

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 5:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.5 ACE AGER ALB ANGPT2 FGF2 FLT1
2 homeostasis/metabolism MP:0005376 10.47 ACE AGER AKR1B1 ALB ANGPT2 FGF2
3 hematopoietic system MP:0005397 10.39 ACE AGER ANGPT2 FGF2 FLT1 ICAM1
4 immune system MP:0005387 10.35 ACE AGER ALB ANGPT2 FLT1 ICAM1
5 growth/size/body region MP:0005378 10.34 ACE AGER AKR1B1 FLT1 ICAM1 IGF1
6 cellular MP:0005384 10.31 AGER ALB ANGPT2 FGF2 FLT1 ICAM1
7 mortality/aging MP:0010768 10.28 ACE AKR1B1 ALB ANGPT2 FGF2 FLT1
8 integument MP:0010771 10.16 AGER ANGPT2 ICAM1 IGF1 INS KDR
9 muscle MP:0005369 10.14 AGER ALB FGF2 FLT1 ICAM1 IGF1
10 nervous system MP:0003631 10.1 ACE FGF2 FLT1 ICAM1 IGF1 INS
11 neoplasm MP:0002006 9.97 ACE ALB FGF2 ICAM1 IGF1 PGF
12 normal MP:0002873 9.91 AGER ALB FLT1 IGF1 INS KDR
13 renal/urinary system MP:0005367 9.81 ACE AGER AKR1B1 ALB IGF1 INS
14 skeleton MP:0005390 9.65 AGER AKR1B1 FGF2 IGF1 INS KDR
15 vision/eye MP:0005391 9.44 ACE AKR1B1 ANGPT2 FGF2 FLT1 ICAM1

Drugs & Therapeutics for Microvascular Complications of Diabetes 5

Drugs for Microvascular Complications of Diabetes 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 403)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
2
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
3
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
4
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
5
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
6
Enalaprilat Approved Phase 4 76420-72-9 6917719
7
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
8
Losartan Approved Phase 4 114798-26-4 3961
9
Doxazosin Approved Phase 4 74191-85-8 3157
10
Ramipril Approved Phase 4 87333-19-5 5362129
11
Liraglutide Approved Phase 4 204656-20-2 44147092
12
Povidone-iodine Approved Phase 4 25655-41-8
13
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
14
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
15
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
16
Insulin glargine Approved Phase 4 160337-95-1
17
Insulin glulisine Approved Phase 4 207748-29-6
18
Iodine Approved, Investigational Phase 4 7553-56-2 807
19
Povidone Approved Phase 4 9003-39-8 131751496
20
Dipivefrin Approved Phase 4 52365-63-6 3105
21
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
22
Nisoldipine Approved Phase 4 63675-72-9 4499
23
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
24
Probucol Approved, Investigational Phase 4 23288-49-5 4912
25
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
26
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
27
Indapamide Approved Phase 4 26807-65-8 3702
28
Atorvastatin Approved Phase 4 134523-00-5 60823
29
Amlodipine Approved Phase 4 88150-42-9 2162
30
Atenolol Approved Phase 4 29122-68-7 2249
31
Clonidine Approved Phase 4 4205-90-7 2803
32
carbamide peroxide Approved Phase 4 124-43-6
33
Insulin lispro Approved Phase 4 133107-64-9
34
Verapamil Approved Phase 4 52-53-9 2520
35
Trandolapril Approved Phase 4 87679-37-6 5484727
36
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
37
Saxagliptin Approved Phase 4 361442-04-8 11243969
38
Metformin Approved Phase 4 657-24-9 14219 4091
39
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
40
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
41
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
42
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
43 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
44
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
45
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
46
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
47
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
48
Captopril Approved Phase 4 62571-86-2 44093
49
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
50
Niclosamide Approved, Investigational, Vet_approved Phase 4 50-65-7 4477

Interventional clinical trials:

(show top 50) (show all 815)
# Name Status NCT ID Phase Drugs
1 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
2 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
3 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
4 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
5 Effects of Glatiramer Acetate (Copaxone) in the Nerve Fiber Layer Thickness and Retinal Function in Diabetic Patients After Pan- Retinal Photocoagulation (PRP), a Double- Masked Randomized Clinical Trial. Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
6 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
7 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
8 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
9 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
10 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
11 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
12 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
13 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
14 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
15 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
16 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
17 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
18 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
19 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
20 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
21 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
22 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
23 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
24 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
25 A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients Completed NCT01664676 Phase 4 Liraglutide;Placebo-liraglutide
26 A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin®/Lucentis®) Compared With Intraocular Triamcinolone (Volon A®) in Patients With Clinical Significant Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
27 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4 Latanoprost
28 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
29 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
30 A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy Completed NCT00363987 Phase 4 Ketosteril®
31 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
32 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH;ACTH
33 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
34 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
35 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil;Candesartan Cilexetil 32mg
36 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
37 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
38 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
39 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
40 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Completed NCT00535925 Phase 4 SoC therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
41 Diabetic Macula Oedema. A Prospective Randomised Study Comparing the Detailed Functional and Anatomical Changes of Repeated Pan Anti-VEGF Therapy With Ranibizumab Versus Conventional Macular Laser Therapy. Completed NCT01223612 Phase 4 Ranibizumab
42 20- Versus 23- Gauge System for Pars Plana Vitrectomy: A Prospective Randomized Clinical Study Completed NCT00411970 Phase 4
43 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
44 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
45 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment. A UK, 18-month, Prospective, Open-label, Multicentre, Single-arm, Phase IIIb Study With 12-month Primary Endpoint, Assessing the Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Diabetic Macular Oedema. Completed NCT01257815 Phase 4 Ranibizumab
46 Yellow Micropulse Laser 577-nm vs Infrared Diode Micropulse Laser 810-nm for the Treatment of Diabetic Macular Edema Completed NCT04359771 Phase 4
47 Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma Completed NCT02647515 Phase 4 ranibizumab
48 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion Completed NCT00682240 Phase 4
49 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
50 Investigator Initiated Observational Study of Intravitreal Aflibercept Injection in Subjects With Diabetic Macular Edema Previously Treated With Ranibizumab or Bevacizumab Completed NCT02559180 Phase 4 aflibercept

Search NIH Clinical Center for Microvascular Complications of Diabetes 5

Inferred drug relations via UMLS 71 / NDF-RT 51 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cochrane evidence based reviews: diabetic retinopathy

Genetic Tests for Microvascular Complications of Diabetes 5

Genetic tests related to Microvascular Complications of Diabetes 5:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 5 29 PON1

Anatomical Context for Microvascular Complications of Diabetes 5

MalaCards organs/tissues related to Microvascular Complications of Diabetes 5:

40
Eye, Endothelial, Retina, Kidney, Bone Marrow, Pituitary, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Microvascular Complications of Diabetes 5:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Outer Nuclear Layer Mature L Cone Cells Affected by disease, potential therapeutic candidate
2 Eye Outer Nuclear Layer Mature M Cone Cells Affected by disease, potential therapeutic candidate
3 Eye Inner Nuclear Layer Mature Muller Glia Cells Affected by disease
4 Eye Outer Nuclear Layer Mature Rod Cells Affected by disease, potential therapeutic candidate
5 Eye Outer Nuclear Layer Mature S Cone Cells Affected by disease, potential therapeutic candidate

Publications for Microvascular Complications of Diabetes 5

Articles related to Microvascular Complications of Diabetes 5:

(show top 50) (show all 23701)
# Title Authors PMID Year
1
Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. 54 61 57 6
11918623 2002
2
A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. 6 54 61 57
9661650 1998
3
Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. 6 57
11335891 2001
4
Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families. 6
11889198 2002
5
LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. 6
11788650 2002
6
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. 6
9011577 1997
7
Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. 54 61
20225131 2010
8
Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor. 61 54
20166888 2010
9
Correlation of electroretinography b-wave absolute latency, plasma levels of human basic fibroblast growth factor, vascular endothelial growth factor, soluble fatty acid synthase, and adrenomedullin in diabetic retinopathy. 61 54
19216096 2010
10
Expression of stromal cell-derived factor-1 in diabetic retinopathy. 54 61
20497701 2010
11
Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy. 54 61
20008515 2010
12
Diabetic retinopathy: An update on treatment. 54 61
20193825 2010
13
Oxidative damage of mitochondrial DNA in diabetes and its protection by manganese superoxide dismutase. 61 54
20088710 2010
14
Retinal overexpression of angiopoietin-2 mimics diabetic retinopathy and enhances vascular damages in hyperglycemia. 61 54
19238311 2010
15
Protein kinase C beta (PRKCB1) and pigment epithelium derived factor (PEDF) gene polymorphisms and diabetic retinopathy in a south Indian cohort. 54 61
20141354 2010
16
Plasma and aqueous humor angiotensin-converting enzyme levels in patients with diabetic retinopathy. 54 61
20373882 2010
17
Masked hypertension, nocturnal blood pressure and retinopathy in normotensive patients with type 1 diabetes. 54 61
19926157 2010
18
Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. 61 54
20142713 2010
19
Sustained regression of florid diabetic retinopathy in a patient with Donohue syndrome (leprechaunism). 61 54
19882513 2010
20
Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. 54 61
19553626 2009
21
Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. 54 61
19646547 2009
22
Genetic polymorphisms in genes encoding antioxidant enzymes are associated with diabetic retinopathy in type 1 diabetes. 61 54
19752172 2009
23
The anti-angiogenic isoforms of VEGF in health and disease. 54 61
19909248 2009
24
Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina. 54 61
19709741 2009
25
Polymorphism of the manganese superoxide dismutase gene but not of vascular endothelial growth factor gene is a risk factor for diabetic retinopathy. 54 61
19628492 2009
26
Effects of trace elements on albumin and lipoprotein glycation in diabetic retinopathy. 61 54
19838431 2009
27
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. 61 54
19526210 2009
28
Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. 61 54
19784389 2009
29
A systematic meta-analysis of genetic association studies for diabetic retinopathy. 61 54
19587357 2009
30
Specific medical intervention for diabetic retinopathy. 61 54
19380207 2009
31
Differences in retinal neovascular tissue and vitreous humour in patients with type 1 and type 2 diabetes. 54 61
19304585 2009
32
Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes. 54 61
19254713 2009
33
Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients. 61 54
19419896 2009
34
Diabetic retinopathy in permanent neonatal diabetes due to Kir6.2 gene mutations: the results of a minimum 2-year follow-up after the transfer from insulin to sulphonylurea. 54 61
19538247 2009
35
Production of scFv antibody fragments from a hybridoma with functional activity against human vascular endothelial growth factor. 61 54
19445630 2009
36
Diabetic retinopathy is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. 54 61
19262488 2009
37
Modulation of thrombospondin 1 and pigment epithelium-derived factor levels in vitreous fluid of patients with diabetes. 61 54
19365032 2009
38
Single nucleotide polymorphisms of vascular endothelial growth factor gene intron 2 are markers for early progression of diabetic retinopathy in Japanese with type 1 diabetes. 54 61
19263526 2009
39
Treating diabetic retinopathy by inhibiting growth factor pathways. 61 54
19337953 2009
40
Low plasma basic fibroblast growth factor is associated with laser photocoagulation treatment in adult type 2 diabetes mellitus from the Veterans Affairs Diabetes Trial. 61 54
19217457 2009
41
Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2. 54 61
18974200 2009
42
[Role of vascular endothelial growth factor in the pathogenesis of diabetic retinopathy]. 54 61
19517837 2009
43
Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. 61 54
19232015 2009
44
Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. 61 54
18709380 2009
45
Analysis of three pigment epithelium-derived factor gene polymorphisms in patients with exudative age-related macular degeneration. 61 54
19223990 2009
46
[Proliferative diabetic retinopathy inauguring gestational diabetes]. 61 54
18514611 2008
47
Regulation of pigment epithelium-derived factor production and release by retinal glial (Müller) cells under hypoxia. 54 61
18676622 2008
48
Vasoinhibins: novel inhibitors of ocular angiogenesis. 61 54
18544641 2008
49
Blood serum levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathy. 61 54
18791689 2008
50
[Positive effects of angiotensin [corrected] receptor blockers on the course of microvascular complications of diabetes mellitus]. 54 61
18830032 2008

Variations for Microvascular Complications of Diabetes 5

ClinVar genetic disease variations for Microvascular Complications of Diabetes 5:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PON1 NM_000446.7(PON1):c.163T>A (p.Leu55Met) SNV risk factor 13736 rs854560 7:94946084-94946084 7:95316772-95316772

Expression for Microvascular Complications of Diabetes 5

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 5.

Pathways for Microvascular Complications of Diabetes 5

Pathways related to Microvascular Complications of Diabetes 5 according to KEGG:

36
# Name Kegg Source Accession
1 AGE-RAGE signaling pathway in diabetic complications hsa04933
2 HIF-1 signaling pathway hsa04066
3 Renin-angiotensin system hsa04614

Pathways related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 VEGFA TEK PRKCB PGF KDR IGF1
2
Show member pathways
13.72 VEGFA TEK PRKCB PGF NOS3 KDR
3
Show member pathways
13.56 TEK PRKCB PGF NOS3 KDR IGF1
4
Show member pathways
13.55 VEGFA TEK PGF KDR INS IGF1
5
Show member pathways
13.42 TEK PRKCB PGF NOS3 KDR IGF1
6
Show member pathways
13.34 VEGFA TEK SERPINE1 PRKCB NOS3 IGF1
7
Show member pathways
13.33 TEK PRKCB PGF KDR IGF1 FLT1
8
Show member pathways
13.32 TEK PRKCB PGF KDR IGF1 FLT1
9
Show member pathways
13.25 VEGFA TEK PRKCB PGF NOS3 KDR
10
Show member pathways
13.07 PRKCB PGF KDR IGF1 FLT1 FGF2
11
Show member pathways
13.02 PRKCB PGF KDR INS IGF1 FLT1
12
Show member pathways
12.92 VEGFA PRKCB PGF KDR IGF1 FLT1
13
Show member pathways
12.86 VEGFA TEK PGF NOS3 KDR INS
14 12.84 VEGFA PRKCB PGF IGF1 FGF2
15
Show member pathways
12.73 PRKCB PGF KDR IGF1 FLT1 FGF2
16
Show member pathways
12.68 VEGFA PRKCB NOS3 KDR ICAM1
17
Show member pathways
12.64 VEGFA PRKCB KDR IGF1 FGF2
18 12.62 VEGFA TEK PRKCB PGF KDR INS
19
Show member pathways
12.53 PRKCB KDR INS IGF1 FLT1
20
Show member pathways
12.51 VEGFA PRKCB NOS3 KDR FLT1 FGF2
21
Show member pathways
12.5 VEGFA TEK PRKCB PGF KDR INS
22
Show member pathways
12.44 PRKCB NOS3 KDR FLT1
23
Show member pathways
12.44 VEGFA PRKCB PGF NOS3 KDR FLT1
24
Show member pathways
12.43 TEK PGF KDR IGF1 FLT1 FGF2
25
Show member pathways
12.43 VEGFA PRKCB NOS3 KDR ICAM1
26
Show member pathways
12.39 VEGFA KDR FLT1 FGF2
27 12.37 VEGFA PRKCB NOS3 KDR FLT1 FGF2
28
Show member pathways
12.34 SERPINE1 INS ICAM1 ALB
29 12.34 VEGFA PRKCB KDR IGF1 FGF2
30
Show member pathways
12.29 PRKCB PGF KDR IGF1 FLT1 FGF2
31 12.15 TEK KDR FLT1 FGF2 ANGPT2
32 12.12 VEGFA NOS3 KDR ICAM1
33 12.03 VEGFA KDR INS IGF1 FGF2 ALB
34 11.91 VEGFA TEK ICAM1 FLT1
35 11.88 VEGFA SERPINE1 PRKCB NOS3 ICAM1 AGER
36
Show member pathways
11.85 PRKCB NOS3 KDR FLT1
37
Show member pathways
11.84 VEGFA PGF NOS3 KDR FLT1
38 11.79 VEGFA IGF1 FGF2
39 11.79 TEK NOS3 KDR FLT1 FGF2 ANGPT2
40 11.73 PRKCB NOS3 INS AGER
41 11.69 VEGFA IGF1 FGF2
42 11.6 KDR INS IGF1 FGF2
43 11.56 VEGFA KDR FGF2
44 11.54 VEGFA INS IGF1 FGF2
45 11.52 VEGFA KDR FGF2
46